Savara Inc
Closed
SectorHealthcare
5.09 -4.14
Overview
Share price change
24h
Min
5.04
Max
5.3
Income | -5M -37M |
|---|---|
Employees | 70 |
EBITDA | -5.5M -39M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +110.75% upside |
Next Earnings | 12 sie 2026 |
|---|
Market Cap | 6.2M 1.1B |
|---|---|
Previous open | 9.23 |
Previous close | 5.09 |
Savara Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Savara Inc Forecast
Price Target
By TipRanks
110.75% upside
12 Months Forecast
Average 11.17 USD 110.75%
High 16 USD
Low 9 USD
Based on 6 Wall Street analysts offering 12 month price targets forSavara Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.